Anabone Injection (Ibandronate Sodium Hydrate)

Adult administration

Administer 3 mg by intravenous injection every 3 months over 15 - 30 seconds.

This medication must only be administered by intravenous injection. Caution is required as injecting into the tissues around arteries or veins may cause tissue damage. Patients with known allergies to this medication or untreated hypocalcemia should not use it. Gastrointestinal symptoms such as gastric inflammation, diarrhea, abdominal pain, dyspepsia, nausea, and constipation may occur during the use of this medication, along with musculoskeletal pain or joint pain, and muscular symptoms. Additionally, symptoms similar to influenza, fatigue, headache, and rashes may occur. Rare side effects such as osteonecrosis of the jaw or external auditory canal have been reported during the use of this medication, thus caution is especially required for cancer patients or those needing dental treatment. If dental treatment is necessary, oral examination prior to treatment is recommended, and excessive dental procedures should be avoided during treatment. This medication can temporarily lower serum calcium levels; therefore, hypocalcemia and any abnormalities in bone and mineral metabolism must be addressed prior to administration. Adequate intake of calcium and vitamin D is important. Patients with impaired renal function or those on medication that may affect the kidneys require regular monitoring and treatment. Severe bone, joint, or muscle pain may occur during the administration of this medication, and if such symptoms appear, consultation with a physician is essential. In addition, pain in the thigh or groin should prompt suspicion of atypical fracture and should be evaluated. Pregnant or breastfeeding women are advised not to use this medication, and safety and efficacy for children under 18 years have not been established. In cases of overdose, liver and kidney function should be carefully monitored, and appropriate treatment should be given if hypocalcemia or hypophosphatemia occurs. This medication should not be mixed with calcium-containing solutions or other intravenous medications and must be diluted with isotonic saline or 5% dextrose solution prior to administration. Used injection needles and syringes must not be reused and should be disposed of in a safe container.

Serious side effects

Urticaria, angioedema, facial swelling/edema, anaphylactic reaction/shock, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, acute renal failure, respiratory distress, allergic reactions, severe skin adverse reactions, multiple organ failure, death, vascular abnormalities (phlebitis/thrombophlebitis), angioedema

Mild side effects

• Gastric inflammation
• diarrhea
• abdominal pain
• dyspepsia
• nausea
• constipation
• musculoskeletal pain
• joint pain
• muscle pain
• influenza-like illness

This medication should be stored in a sealed container to avoid exposure to air and kept at a temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication for a longer time.

Appearance

A colorless, transparent solution filled in a colorless, transparent glass prefilled syringe, equipped with a single-use injection needle.

Package unit

3ml/prefilled syringe x 1